Ruti Aga's Six-Year Ban: Two Years for the Drug, Four for the Paper

The prescription carried a drug name — methylprednisolone, for the knee. It carried the stamp of a clinic that did not exist. The "doctor" who wrote it was a family member with no medical registration, who explained under questioning that he had pulled an old prescription pad from a former workplace. The clinic that supposedly issued that pad disowned it outright. That single sheet of paper cost four years. The drug it was written for cost two. Six in total — the arithmetic recorded in the Athletics Integrity Unit's statement released on a Thursday, for the Ethiopian marathoner Ruti Aga. The count runs from 10 September, the same date her provisional suspension began. I have spent twenty-five years sitting in these rooms. In Bhubaneswar in 2026, from the stadium-announcer's chair at the Asian Championships, I learned that you cannot read an athlete's introduction aloud until you have found the one number that bends the story. At Gold Coast in 2026 a syringe taught me that recovery is a public performance. And at the Inspiration Games in 2026, calling thirty events across seven empty venues off monitors, I learned the crowd's silence before I ever learned its roar. All of it points the same way: in doping cases the real story is never the drug. It is the paper. Everyone remembers the drug's name. Nobody remembers who wrote the sheet, who stamped it, who waved it through. Aga is thirty-two. In March she won a half marathon in China. The time is nowhere in the record — no splits, no field strength, no conditions. Reading form off that win would be invention. What is documented is this: a sample collected after the race returned methylprednisolone, and Aga said it was an injection taken to treat a knee injury. A technical correction is required here, because most reports have called it a prohibited steroid, and that is only half the truth. Methylprednisolone is not an anabolic steroid. It is a glucocorticoid — class S9 on the WADA Prohibited List. And S9 carries a double condition: prohibited in-competition only, and only by injection, oral or rectal route. A knee injection given out of competition is not, by itself, a violation. It becomes one when residue is still present on race day. The testing window for a road race opens at 23:59 the night before. That is the hinge on which this entire case turns — not steroid use, but route and timing. An athlete with genuine medical records has two doors: obtain a Therapeutic Use Exemption, or wait out the washout period. Neither door was used. A third was chosen instead — the one that involved manufacturing a prescription. Her career record belongs in the same paragraph, because the ban does not erase it. She won the 2026 Tokyo Marathon, a World Marathon Major. She has three second-place finishes at Majors. Her best sits around 2:18 — second at Berlin 2026, roughly 2:20 in Tokyo 2026. Those figures are not in the AIU statement; they come from external records and require separate verification. The violation is anchored to that March race in China, so results before it are not automatically annulled. The statement does not specify the disqualification's scope — though standard practice is that the competition where the sample was collected loses its result and its prize money. Start with the arithmetic, because it explains the most. Two years for the presence violation — a prohibited substance in the sample. Four years for tampering — misleading information and a fabricated document. Six in total. That arithmetic is itself a finding. Had the panel judged the athlete's fault to be anything less than significant, the two years could have been cut — in some cases down to a reprimand. The full two-year term standing intact tells us the relief door was shut. And she shut it herself. The moment a forged prescription was produced, the argument that the treatment was real collapsed. If real records existed, real records would have been shown. A forged prescription is a confession that there was nothing worth showing. Three verifications, from three separate directions, landed on the same answer. The clinic did not exist. The writer had no medical registration. The clinic disowned the pad. Not one check passed. That is why the standard four years for tampering arrived without any discount. Now the part nobody looked at. The knee-injury explanation is mechanically entirely credible. Intra-articular methylprednisolone for knee synovitis is ordinary sports-medicine practice in distance running. That credibility is exactly what makes the case sadder, because it suggests the treatment may genuinely have happened — it simply had no paper existence. And why would it have none? Because there was no credentialed team physician. The "doctor" was family. This is not a filing error. It is the signature of an athlete running on a wholly informal medical network, where the injection is available and the receipt is not, where the treatment happens and the record does not. One detail deserves registering even though the statement does not spell it out: the tampering charge was not built on a document alone. It was built on an interview — on statements made under questioning. Language and translation conditions in AIU interviews with Ethiopian athletes have been a recurring point of contention. Which language the "old prescription pad" answer was given in, before which interpreter, in what room, remains an open question. I am not alleging misconduct. I am saying that a four-year sanction resting entirely on a statement deserves the same scrutiny as the prescription did. The patch notes arrived before the players did. In 2026 WADA amended the Prohibited List so that a glucocorticoid injection during competition became a straight violation — previously it moved under the shadow of treatment, afterwards it did not. For the people who make their living on the road-racing calendar, that was the season's biggest system update, and many never received it. Aga's case is what that update looks like when it lands on someone. I think of the Gold Coast syringe in 2026. Even then the question was not the drug. It was how recovery runs inside a team, and who keeps its record. Eight years on, the same question, now shrunk to one family's prescription pad. The economic logic underneath is this: China's label races are a distinct income tier for East African marathoners. In the gap between Majors they pay appearance fees, demand less, and fill the calendar. For a 2:18–2:20 runner the model is rational — few races, chosen races, decent money. That same tier is now the AIU's highest-yield testing ground. The fee economy and the testing economy are colliding in the same race, and in a collision the athlete always falls first. And the effect on Ethiopia? None. The depth in women's marathoning is such that a 2:18 performer is not automatically selectable. Three Major runner-up finishes are superb, and they are not championship medals. One thirty-two-year-old stepping out does not move Ethiopian medal capacity by an inch. That is the coldest truth here: the damage belongs to one woman. No federation statement is even on the record — the release speaks only for the AIU, and the Ethiopian federation is silent. The age math is just as blunt. Six years from 10 September puts her return at thirty-eight. At that age, with a doping record, inside that depth, no selector has an argument for picking her. On paper it is a six-year ban. In career terms it is a lifetime one. Now the turn where the easy road has to be abandoned. The easy road says: caught, six years, correct. I will not take it, because the proportion is strange. Look at what the substance was. A glucocorticoid. There is no established endurance benefit. It reduces swelling and suppresses pain. It is the drug that lets an injured runner start, not the drug that makes her faster. It drew two years — not because she gained strength, but because residue survived into race day. A technical lapse. The real four years were for the paper. And the question follows: does a system that gave an injured thirty-two-year-old no team physician get to make the forged prescription the heaviest part of the sentence? I am not arguing the forgery should be excused. I am arguing that the penalty landed on the symptom, not the cause. The cause was injury, an informal network, and an appearance fee waiting in China. And no name from that cause appears in any statement. Whoever advised on the document, whoever accepted it, whoever said it would be fine — the AIU names only the one family member. Whether the agent was investigated is unknown. Second, the mislabelling the media has already committed and will keep citing: calling it a steroid. When an African road runner's case is filed under anabolic steroids, the comparison goes wrong. The sentence is misread, and the case for leniency ends up resting on the wrong data. That is not a small slip. One wrong category shifts the whole argument. Third, the thing that stings most: Tokyo 2026 is not erased. She won that race, and the win is hers. Gilding it into a moral medal would be just as wrong as painting it over with the ban's ink. Hold both: a genuinely excellent marathoner, and a woman who had a sheet of paper made that ate the rest of her career. That is the next page in the fifth-place ledger I have kept for thirty years — where a loss gets recorded, not deleted. The AIU's enforcement frontier has moved. The question used to be what was in the sample. The question now is whether the paper is real. That shift matters, because in the training clusters where these informal medical networks operate, a prescription pad does not belong to one athlete. The appeal window is open — typically around twenty-one days from the reasoned decision — but a document-based finding is hard to overturn. The question is not whether Ruti Aga comes back. The question is who, the next time an injured runner needs a knee injection and has no team doctor, will put an old prescription pad in her hand. That name will not appear in any statement.